Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanton R Mehr

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
The American Journal of Managed Care|January 11, 2013
Strategies to increase the value of colon cancer medicationsMarj P Zimmerman, Stanton R Mehr
American Health & Drug Benefits|May 4, 2017
Is a Biologic Produced 15 Years Ago a Biosimilar of Itself Today?Stanton R Mehr, Marj P Zimmerman
The American Journal of Managed Care|June 4, 2013
Chemoprevention in prostate cancer: identifying patients at greatest risk may provide greatest valueMarj P Zimmerman, Stanton R Mehr
The American Journal of Managed Care|January 26, 2015
Nonincretin drugs in later-stage developmentMarj P Zimmerman, Stanton R Mehr
The American Journal of Managed Care|January 26, 2015
Targeted programmed cell death in lung cancer treatmentMarj P Zimmerman, Stanton R Mehr
The American Journal of Managed Care|September 27, 2012
The keys to obtaining best value in non-small cell lung cancerMarj P Zimmerman, Stanton R Mehr
The American Journal of Managed Care|January 26, 2015
The how and why of stress, diabetes, and the brainMark Feinglos, Richard Surwit, Stanton R Mehr
The American Journal of Managed Care|April 4, 2012
Targeted products yield most promising resultsJennifer Klem, Stanton R Mehr, Marj Pestil Zimmerman
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
The American Journal of Managed Care|January 11, 2013
Strategies to increase the value of colon cancer medicationsMarj P Zimmerman, Stanton R Mehr
American Health & Drug Benefits|May 4, 2017
Is a Biologic Produced 15 Years Ago a Biosimilar of Itself Today?Stanton R Mehr, Marj P Zimmerman
The American Journal of Managed Care|June 4, 2013
Chemoprevention in prostate cancer: identifying patients at greatest risk may provide greatest valueMarj P Zimmerman, Stanton R Mehr
The American Journal of Managed Care|January 26, 2015
Nonincretin drugs in later-stage developmentMarj P Zimmerman, Stanton R Mehr
The American Journal of Managed Care|January 26, 2015
Targeted programmed cell death in lung cancer treatmentMarj P Zimmerman, Stanton R Mehr
The American Journal of Managed Care|September 27, 2012
The keys to obtaining best value in non-small cell lung cancerMarj P Zimmerman, Stanton R Mehr
The American Journal of Managed Care|January 26, 2015
The how and why of stress, diabetes, and the brainMark Feinglos, Richard Surwit, Stanton R Mehr
The American Journal of Managed Care|April 4, 2012
Targeted products yield most promising resultsJennifer Klem, Stanton R Mehr, Marj Pestil Zimmerman
Pageof 4